Table 7.

Predictors of i‐TTR (%) in Warfarin Patients by Multiple Linear Regression Modeling Using Race in Model Rather Than Region

Baseline Characteristic	Multivariable
	Parameter Estimate	F	P Value	Partial R2
VKA experience		239.37	<0.0001	0.0690
Warfarin experienced	Ref
VKA experienced/warfarin naïve	−11.965
VKA naïve	−4.149
CHF	−4.942	92.90	<0.0001	0.0132
Female	−14.294	37.94	<0.0001	0.0054
Race		20.47	<0.0001	0.0088
White	Ref
Black	1.924
Asian	−5.919
Other	−3.836
eGFR, 10 mL/min per 1.73 m2				0.0048
Linear	−11.123	24.26	<0.0001
Quadratic	0.331	14.26	0.0002
Hemoglobin, 2 g/L				0.0043
Linear	−15.327	24.42	<0.0001
Quadratic	0.559	15.92	<0.0001
Systolic BP	−0.055	13.42	0.0003	0.0019
Alcohol consumption, 12 mo		10.09	<0.0001	0.0044
Abstinent	Ref
Light	2.427
Moderate	4.541
Heavy	−3.944
COPD	−2.305	8.44	0.0037	0.0012
BMI				0.0022
Linear	0.422	2.80	0.095
Quadratic	−0.004	1.13	0.29
Diabetes	−0.638	1.57	0.21	0.0002
Medications at entry to the trial
Amiodarone	−4.395	23.89	<0.0001	0.0034
Statin	2.568	26.35	<0.0001	0.0038
Aspirin	−0.782	2.02	0.16	0.0003

i‐TTR indicates individual patient‐level time in therapeutic range; VKA, vitamin K antagonist; CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; BP, blood pressure; COPD, chronic obstructive pulmonary disease; BMI, body mass index.